Atherosclerosis
Volume 191, Issue 1 , Pages 48-53 , March 2007

Haptoglobin genotype modulates the balance of Th1/Th2 cytokines produced by macrophages exposed to free hemoglobin

Received 21 February 2006 ,Accepted 20 April 2006.

References 

  1. Rother RP, Bell L, Hillmen P, et al. The clinical sequalae of intravascular hemolysis and extracellular plasma hemoglobin. A novel mechanism of human disease. JAMA. 2005;293:1653–1662
  2. Frank M, Lache O, Enav B, et al. Structure/function analysis of the anti-oxidant properties of haptoglobin. Blood. 2001;98:3693–3698
  3. Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the hemoglobin scavenger receptor. Nature. 2001;409:198–201
  4. Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 2003;349:2316–2325
  5. Borsody M, Burke A, Coplin W, et al. Haptoglobin and the development of cerebral artery vasospasm after subarachnoid hemorrhage. Neurology. 2006;66:634–640
  6. Bowman BH, Kurosky A. Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet. 1982;12:189–261
  7. Levy AP, Hochberg I, Jablonski K, et al. Haptoglobin phenotype and the risk of cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Colloid Cardiol. 2002;40:1984–1990
  8. Suleiman M, Aronson D, Asleh R, et al. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes. 2005;19:2802–2806
  9. Miller-Lotan R, Herskowitz Y, Kalet-Litman S, et al. Increased renal hypertrophy in diabetic mice genetically modified at the haptoglobin locus. Diabetes Met Res Rev. 2005;21:332–337
  10. Asleh R, Marsh S, Shiltruck M, et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res. 2003;92:1193–1200
  11. Asleh R, Guetta J, Kalet-Litman S, et al. Haptoglobin genotype and diabetes dependent differences in iron mediated oxidative stress in vitro and in vivo. Circ Res. 2005;96:435–441
  12. Phillippidis P, Mason JC, Evans BJ, et al. Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme-oxygenase-1 synthesis: anti-inflammatory monocyte–macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res. 2004;94:119–126
  13. Ritter M, Buechler C, Kapinsky M, et al. Interaction of CD163 with the regulatory subunit of casein kinase (CKII) and dependence of CD163 signaling on CKII and protein kinase C. Eur J Immunol. 2001;31:999–1009
  14. Antoniv TT, Park-Min KH, Ivashkiv LB. Kinetics of Il-10 induced gene expression in human macrophages. Immunobiology. 2005;210:87–95
  15. Tilg H, Dinarello CA, Mier JW. Il-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today. 1997;9:428–432
  16. Yang Z, Zingarelli B, Szabo C. Crucial role of endogenous interleukin-10 production in myocardial ischemia/reperfusion injury. Circulation. 2000;101:1019–1026
  17. Potteaux S, Esposito B, Oostrom OV, et al. Leukocyte derived interleukin-10 is required for protection against atherosclerosis in low density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol. 2004;24:1474–1478
  18. Waehre T, Halvorsen B, Damas JK, et al. Inflammatory imbalance between Il-10 and TNFa in unstable angina potential plaque stabilizing effects of Il-10. Eur J Clin Invest. 2002;32:803–810
  19. Schieffer B, Selle T, Hilfiker A, et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation. 2004;110:3493–3500
  20. Ostrowski SR, Plomgaard P, Fishcer CP, et al. Interleukin-6 infusion during human endotoxemia inhibits in vitro release of the urokinase receptor form peripheral blood mononuclear cells. Scand J Immunol. 2005;61:197–206
  21. Tilg H, Kaser A. Il-6 and arthritis: a detrimental or beneficial mediator?. IDrugs. 1998;1:890–895
  22. Petersen AMW, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol. 2005;98:1154–1162
  23. Shingu M, Miyauchi S, Nagai Y, et al. The role of Il-4 and Il-6 in Il-1 dependent cartilage matrix degradation. Br J Rheum. 1995;34:101–106
  24. Xing Z, Gauldie J, Cox G, et al. Il-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 1998;101:311–320
  25. Gadient RA, Patterson PH. Leukemia inhibitory factor, interleukin-6 and other cytokines using the gp130 transducing receptor: roles in inflammation and injury. Stem Cells. 1999;17:127–137
  26. Ward NS, Waxman AB, Homer RJ, et al. Interleukin-6 induced protection in hyperoxic acute lung injury. Am J Respir Cell Mol Biol. 2000;22:535–542
  27. Lebel E, Vallieres L, Rivest S. Selective involvement of interleukin-6 in the transcriptional activation of the suppressor of cytokine signaling-3 in the brain during systemic immune challenges. Endocrinology. 2000;141:3749–3763
  28. Chen XP, Losman JA, Rothman P. SOCS proteins, regulators of intracellular signaling. Immunity. 2000;13:287–290
  29. Garn H, Siese A, Stumpf S, et al. Shift toward an alternatively activated macrophage response in lungs of NO2-exposed rats. Am J Respir Cell Mol Biol. 2003;28:386–396
  30. Djemadji ON, Goerdt S, Kodelja V, et al. Immunohistochemical identification of type II alternatively activated dendritic macrophages (RM 3/1 +++, MS-11+/− 25F9-) in psoriatic dermis. Arch Derm Res. 1996;288:757–764

PII: S0021-9150(06)00245-0

doi: 10.1016/j.atherosclerosis.2006.04.032

Atherosclerosis
Volume 191, Issue 1 , Pages 48-53 , March 2007

Article Tools

* Image Usage & Resolution